RECEIPT &

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231

Attorney Docket No.: 15280W003000

on June 6, 2000

By: Dari Flangas

FILE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Unassigned

Hyun K. Kim, et al.

Art Unit:

1615

Application No.: 09/526,855

i Omi. 1013

...,

REQUEST FOR CORRECTED FILING RECEIPT

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-α-SUBSTITUTED-11-β-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There are errors in the Applicant(s) names that should read as follows:

Carmie K. Acosta

Anne Marie Simmons

Also, the title should read as follows: STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-α-SUBSTITUTED-11-β-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS

The correction is due to applicants' error and the fee therefor, pursuant to 37 CFR §1.19(h), of \$25 is to be charged to Deposit Account No. 20-1430. Please charge any additional

Attorney Docket No.: 15280W003000 Application No.: 09/526,855

Page 2

fees or credit overpayment to the Deposit Account No. 20-1430. This Petition is submitted in triplicate.

Respectfully submitted,

gen a Garrettg. No. 37,330

TOWNSEND and TOWNSEND and CREW I

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

EGW/lls

SF 1101862 v1






**Bib Data Sheet** 



# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBE 09/526,855	FILING DATE 03/17/2000 RULE _		_	L <b>ASS</b> 424	GROUP ART UNIT 1615		TINU	ATTORNEY DOCKET NO. 15280W003000	
Hyun K. Kim, Bethesda, MD; Richard P. Blye, Highland, MD; Pemmaraju N. Rao, San Antonio, TX; James W. Cessac, San Antonio, TX; Carmie K. Acosta, San Antonio, TX; Anne Marie Simmons, San Antonio, TX;  *** CONTINUING DATA **********************************									
Foreign Priority claimed				STATE OR COUNTRY MD	1				INDEPENDENT Claims 1
<b>ADDRESS</b>									
TITLE Structural modification of 19-Norprogesterone I: 17-alpha-substituted-11-Beta-substituted-4-Aryl and 21-substituted 19-Norpregnadienedione as new Antiprogestational agents									
FILING FEE F	EES: Authority has been given in Paper o to charge/credit DEPOSIT ACCOUNT o for following:					All Fees  1.16 Fees (Filing)  1.17 Fees (Processing Ext. of time)  1.18 Fees (Issue)  Other  Credit			





## 80W-00 3000 LS

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS

Washington, D.C. 20231

TOT IND CLAIMS **DRAWINGS** CLAIMS

09/526,855

APPLICATION NUMBER

FIL FEE REC'D GRP ART UNIT

1615

ATTY.DOCKET.NO

03/17/2000

FILING DATE

0

15280W003000

11

50

1

20350

TOWNSEND AND TOWNSEND AND CREW LLP

TWO EMBARCADERO CENTER

EIGHTH FLOOR

SAN FRANCISCO, CA 94111

Date Mailed: 05/18/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Carnie

Hyun K. Kim, Bethesda, MD;

Richard P. Blye, Highland, MD;

Pemmaraju N. Rao, San Antonio, TX;

James W. Cessac, San Antonio, TX;

Garme K. Acosta, San Antonio, TX;

Marie Simmon Anne, San Antonio, TX;

Anne Marie Simmons

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/180,132 05/24/1999

WHICH IS A 371 OF PCT/US97/07373 04/30/1997

AND CLAIMS BENEFIT OF 60/016,628 05/01/1996

Foreign Applications

If Required, Foreign Filing License Granted 05/18/2000

Title

RECEINED

Structural modification of 19-Norprogesterone I: 17-X-substituted-11-X-substituted-4-Aryl, and 08 1871 00 98:2 No 21-substituted 19-Norpregnadienedione as new Antiprogestational agents

Preliminary Class

424

Data entry by : BURNS, ERIC

Team: OIPE

Date: 05/18/2000

. | 1881/8 4/118 1911/1 148/5 1516 1111/1 1881/6 14

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:



Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231